Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failure
Introduction and objectives: Glycoprotein carbohydrate antigen 125 (CA125) has been proposed as a new biomarker in heart failure (HF). Its potential prognostic role in chronic (CHF) and acute HF (AHF) is still underrecognized. Methods: Observational prospective study. The aims of this study were to...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Permanyer
2021-01-01
|
Series: | Spanish Journal of Medicine |
Subjects: | |
Online Access: | https://www.spanishjmed.com/frame_esp.php?id=24 |
id |
doaj-84eea5791c524527a77096cdf30f9a32 |
---|---|
record_format |
Article |
spelling |
doaj-84eea5791c524527a77096cdf30f9a322021-06-15T21:32:12ZengPermanyerSpanish Journal of Medicine2696-56312021-01-011110.24875/SJMED.M21000008Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failureClaudia Josa-Laorden0Ignacio Giménez-López1Charles Butcher2Marta Sánchez-Marteles3José Rubio-Gracia4Juan Ignacio Pérez-Calvo5Instituto de Investigación Sanitaria Aragón (IIS-Aragón); Internal Medicine Department, Hospital Universitario Lozano Blesa; Zaragoza, SpainInstituto de Investigación Sanitaria Aragón (IIS-Aragón); Facultad de Medicina, Universidad de Zaragoza; Insituto Aragonés de Ciencias de la Salud (IACS). Zaragoza. SpainNational Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, United KingdomInternal Medicine Service, Hospital Clínico Universitario Lozano Blesa; Instituto de Investigación Sanitaria de Aragón; Zaragoza, SpainInstituto de Investigación Sanitaria Aragón (IIS-Aragón); Internal Medicine Department, Hospital Universitario Lozano Blesa; Zaragoza, SpainInstituto de Investigación Sanitaria Aragón (IIS-Aragón); Internal Medicine Department, Hospital Universitario Lozano Blesa; Insituto Aragonés de Ciencias de la Salud (IACS). Zaragoza. SpainIntroduction and objectives: Glycoprotein carbohydrate antigen 125 (CA125) has been proposed as a new biomarker in heart failure (HF). Its potential prognostic role in chronic (CHF) and acute HF (AHF) is still underrecognized. Methods: Observational prospective study. The aims of this study were to analyze prognostic information (mortality at 1 and 12 months after discharge) yielded by serum CA125 in AHF and whether changes in concentrations from admission to discharge improved risk stratification. Results: Two hundred and four patients with AHF were included (median age 81 ± 4 years). Both CA125, at admission and discharge, were associated with short and long-term prognosis. CA125 at discharge had the greatest area under the curve (AUC) for predicting HF mortality (AUC = 0.735, 95% CI 0.54 - 0.93 p = 0.003). Moreover, CA125 above median on admission and discharge, increased the risk of long-term mortality in the multivariate study (Admission CA125: Exp[B] = 2.16; p = 0.032 and discharge CA125: Exp[B] = 3.15; p = 0.023). In addition, a rise of CA125 during admission (56% of patients) was associated with higher mortality at 12 months (p = 0.035), especially among patients with CA125 > 55UI/mL at admission. Conclusions: Concentrations of serum CA125 measured during acute decompensation of HF may help identify patients with poor prognosis after discharge. The lack of CA125 decrease during hospitalization, despite clinical improvement, is related to long-term poor outcomes. https://www.spanishjmed.com/frame_esp.php?id=24CA125. Heart failure. Prognosis. Congestion. Biomarker. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claudia Josa-Laorden Ignacio Giménez-López Charles Butcher Marta Sánchez-Marteles José Rubio-Gracia Juan Ignacio Pérez-Calvo |
spellingShingle |
Claudia Josa-Laorden Ignacio Giménez-López Charles Butcher Marta Sánchez-Marteles José Rubio-Gracia Juan Ignacio Pérez-Calvo Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failure Spanish Journal of Medicine CA125. Heart failure. Prognosis. Congestion. Biomarker. |
author_facet |
Claudia Josa-Laorden Ignacio Giménez-López Charles Butcher Marta Sánchez-Marteles José Rubio-Gracia Juan Ignacio Pérez-Calvo |
author_sort |
Claudia Josa-Laorden |
title |
Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failure |
title_short |
Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failure |
title_full |
Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failure |
title_fullStr |
Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failure |
title_full_unstemmed |
Prognostic value of glycoprotein CA125 and their time-line changes in decompensated heart failure |
title_sort |
prognostic value of glycoprotein ca125 and their time-line changes in decompensated heart failure |
publisher |
Permanyer |
series |
Spanish Journal of Medicine |
issn |
2696-5631 |
publishDate |
2021-01-01 |
description |
Introduction and objectives: Glycoprotein carbohydrate antigen 125 (CA125) has been proposed as a new biomarker in heart failure (HF). Its potential prognostic role in chronic (CHF) and acute HF (AHF) is still underrecognized. Methods: Observational prospective study. The aims of this study were to analyze prognostic information (mortality at 1 and 12 months after discharge) yielded by serum CA125 in AHF and whether changes in concentrations from admission to discharge improved risk stratification. Results: Two hundred and four patients with AHF were included (median age 81 ± 4 years). Both CA125, at admission and discharge, were associated with short and long-term prognosis. CA125 at discharge had the greatest area under the curve (AUC) for predicting HF mortality (AUC = 0.735, 95% CI 0.54 - 0.93 p = 0.003). Moreover, CA125 above median on admission and discharge, increased the risk of long-term mortality in the multivariate study (Admission CA125: Exp[B] = 2.16; p = 0.032 and discharge CA125: Exp[B] = 3.15; p = 0.023). In addition, a rise of CA125 during admission (56% of patients) was associated with higher mortality at 12 months (p = 0.035), especially among patients with CA125 > 55UI/mL at admission. Conclusions: Concentrations of serum CA125 measured during acute decompensation of HF may help identify patients with poor prognosis after discharge. The lack of CA125 decrease during hospitalization, despite clinical improvement, is related to long-term poor outcomes.
|
topic |
CA125. Heart failure. Prognosis. Congestion. Biomarker. |
url |
https://www.spanishjmed.com/frame_esp.php?id=24 |
work_keys_str_mv |
AT claudiajosalaorden prognosticvalueofglycoproteinca125andtheirtimelinechangesindecompensatedheartfailure AT ignaciogimenezlopez prognosticvalueofglycoproteinca125andtheirtimelinechangesindecompensatedheartfailure AT charlesbutcher prognosticvalueofglycoproteinca125andtheirtimelinechangesindecompensatedheartfailure AT martasanchezmarteles prognosticvalueofglycoproteinca125andtheirtimelinechangesindecompensatedheartfailure AT joserubiogracia prognosticvalueofglycoproteinca125andtheirtimelinechangesindecompensatedheartfailure AT juanignacioperezcalvo prognosticvalueofglycoproteinca125andtheirtimelinechangesindecompensatedheartfailure |
_version_ |
1721375723527077888 |